Fifteen variants in BRCA1 and 28 variants in BRCA2 were filtered out due to insufficient evidence in ClinVar, with a high fraction (47% and 71%, respectively) identified on-tumor (i.e., in breast/ovarian/pancreatic/prostate cancers), as expected for true pathogenic germline variants (Supplementary Fig. 5B). This evidence concerns the gene BRCA1 and prostate carcinoma.